(Hypertension. 1996;28:409-413.)
© 1996 American Heart Association, Inc.
Articles |
A Vascular Modulator, Hepatocyte Growth Factor, Is Associated With Systolic Pressure
the Department of Geriatric Medicine (Y.N., R.M., S.N., M.A., A.M., J.H., T.O.) and Division of Biochemistry, Department of Oncology, Biomedical Research Center (K.M., T.N.), Osaka (Japan) University Medical School.
Correspondence to Toshio Ogihara, MD, PhD, Department of Geriatric Medicine, Osaka University Medical School, 2-2 Yamada-oka, Suita 565, Japan.
Endothelial cells are known to secrete various antiproliferative and vasodilating factors, such as nitric oxide and natriuretic peptides. The presence of endothelial dysfunction, well known in hypertensive individuals, potentially results in the development and progression of atherosclerosis. Therefore, it is important to know the factors that might influence endothelial cell growth. We examined the mitogenic actions of hepatocyte growth factor (HGF) on human endothelial and vascular smooth muscle cells. Exogenously added human recombinant HGF stimulated endothelial but not vascular smooth muscle cell growth in a dose-dependent manner. We also compared the mitogenic action of HGF with that of basic fibroblast growth factor and vascular endothelial growth factor. Interestingly, the mitogenic action of HGF on endothelial cells was greater than the actions of basic fibroblast growth factor and vascular endothelial growth factor, whereas basic fibroblast growth factor but not HGF and vascular endothelial growth factor stimulated vascular smooth muscle cell growth. Given the characteristics of HGF as an endothelium-specific growth factor, we evaluated the relationship of circulating HGF and blood pressure in normotensive and hypertensive subjects. Serum HGF concentration has been reported to be elevated in response to organ damage, such as in hepatitis and nephritis, and recent findings show that HGF may play an important role in tissue regeneration. We hypothesized that HGF might contribute to the protection or repair of vascular endothelial cells. If so, serum HGF level might be elevated in response to endothelial cell damage induced by hypertension. To test this hypothesis, we measured serum levels of HGF, lipoprotein(a), plasminogen activator inhibitor-1, tissue plasminogen activator, total cholesterol, and blood pressure in 41 normotensive and hypertensive subjects without liver, kidney, or lung damage. Serum HGF concentration was significantly correlated with systolic pressure (P<.01, r=.43) but not diastolic pressure. Serum HGF concentration in hypertensive subjects was significantly higher than in normotensive subjects. None of the other factors showed any correlation with blood pressure. We have demonstrated that HGF is an endothelium-specific growth factor whose serum concentration is significantly associated with systolic pressure. These results suggest that HGF secretion might be elevated in response to high blood pressure as a counterregulatory system against endothelial dysfunction.
Key Words: atherosclerosis • growth substances • vascular remodeling • growth factors, endothelial
This article has been cited by other articles:
 |
|
 |
|
  F. Sanada, Y. Taniyama, K. Iekushi, J. Azuma, K. Okayama, H. Kusunoki, N. Koibuchi, T. Doi, Y. Aizawa, and R. Morishita Negative Action of Hepatocyte Growth Factor/c-Met System on Angiotensin II Signaling via Ligand-Dependent Epithelial Growth Factor Receptor Degradation Mechanism in Vascular Smooth Muscle Cells Circ. Res., September 25, 2009; 105(7): 667 - 675. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-W. Lin, W. H.-H. Sheu, W.-J. Lee, Y.-T. Chen, T.-J. Liu, C.-T. Ting, and W.-L. Lee Circulating Hepatocyte Growth Factor Level but Not Basic Fibroblast Growth Factor Level Is Elevated in Angiography-Proven Symptomatic Peripheral Artery Disease Angiology, September 1, 2007; 58(4): 420 - 428. [Abstract] [PDF]
|
|
|
|
 |
|
 E. Shi, X. Jiang, T. Kazui, N. Washiyama, K. Yamashita, H. Terada, and A. H. M. Bashar Nonviral gene transfer of hepatocyte growth factor attenuates neurologic injury after spinal cord ischemia in rabbits J. Thorac. Cardiovasc. Surg., October 1, 2006; 132(4): 941 - 947. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Ota, Y. Sawa, S. Iwai, T. Kitajima, Y. Ueda, C. Coppin, H. Matsuda, and Y. Okita Fibronectin-Hepatocyte Growth Factor Enhances Reendothelialization in Tissue-Engineered Heart Valve Ann. Thorac. Surg., November 1, 2005; 80(5): 1794 - 1801. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Sakaguchi, K. Tambara, Y. Sakakibara, M. Ozeki, M. Yamamoto, G. Premaratne, X. Lin, K. Hasegawa, Y. Tabata, K. Nishimura, et al. Control-Released Hepatocyte Growth Factor Prevents the Progression of Heart Failure in Stroke-Prone Spontaneously Hypertensive Rats Ann. Thorac. Surg., May 1, 2005; 79(5): 1627 - 1634. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Morishita, M. Aoki, and T. Ogihara Does gene therapy become pharmacotherapy? Exp Physiol, May 1, 2005; 90(3): 307 - 313. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Nanba, S. Kuroda, T. Ishikawa, K. Houkin, and Y. Iwasaki Increased Expression of Hepatocyte Growth Factor in Cerebrospinal Fluid and Intracranial Artery in Moyamoya Disease Stroke, December 1, 2004; 35(12): 2837 - 2842. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Morishita, M. Aoki, N. Hashiya, H. Makino, K. Yamasaki, J. Azuma, Y. Sawa, H. Matsuda, Y. Kaneda, and T. Ogihara Safety Evaluation of Clinical Gene Therapy Using Hepatocyte Growth Factor to Treat Peripheral Arterial Disease Hypertension, August 1, 2004; 44(2): 203 - 209. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Rehman, R. V. Considine, J. E. Bovenkerk, J. Li, C. A. Slavens, R. M. Jones, and K. L. March Obesity is associated with increased levels of circulating hepatocyte growth factor J. Am. Coll. Cardiol., April 16, 2003; 41(8): 1408 - 1413. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. S. Malatino, A. Cataliotti, F. A. Benedetto, B. Stancanelli, I. Bellanuova, P. Belluardo, L. Bonaiuto, G. Tripepi, F. Mallamaci, P. Castellino, et al. Hepatocyte Growth Factor and Left Ventricular Geometry in End-Stage Renal Disease Hypertension, January 1, 2003; 41(1): 88 - 92. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Nakagami, R. Morishita, K. Yamamoto, Y. Taniyama, M. Aoki, K. Yamasaki, K. Matsumoto, T. Nakamura, Y. Kaneda, and T. Ogihara Hepatocyte Growth Factor Prevents Endothelial Cell Death Through Inhibition of bax Translocation From Cytosol to Mitochondrial Membrane Diabetes, August 1, 2002; 51(8): 2604 - 2611. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Purdie, G. St.J. Whitley, A. P. Johnstone, and J. E. Cartwright Hepatocyte growth factor-induced endothelial cell motility is mediated by the upregulation of inducible nitric oxide synthase expression Cardiovasc Res, June 1, 2002; 54(3): 659 - 668. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Borawski and M. Mysliwiec Serum hepatocyte growth factor is associated with viral hepatitis, cardiovascular disease, erythropoietin treatment, and type of heparin in haemodialysis patients Nephrol. Dial. Transplant., April 1, 2002; 17(4): 637 - 644. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. C. Berk Vascular Smooth Muscle Growth: Autocrine Growth Mechanisms Physiol Rev, July 1, 2001; 81(3): 999 - 1030. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Yamamoto, R. Morishita, S.-i. Hayashi, H. Matsushita, H. Nakagami, A. Moriguchi, K. Matsumoto, T. Nakamura, Y. Kaneda, and T. Ogihara Contribution of Bcl-2, but Not Bcl-xL and Bax, to Antiapoptotic Actions of Hepatocyte Growth Factor in Hypoxia-Conditioned Human Endothelial Cells Hypertension, May 1, 2001; 37(5): 1341 - 1348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Matsumoto, R. Morishita, A. Moriguchi, N. Tomita, M. Aoki, H. Sakonjo, K. Matsumoto, T. Nakamura, J. Higaki, and T. Ogihara Inhibition of Neointima by Angiotensin-Converting Enzyme Inhibitor in Porcine Coronary Artery Balloon-Injury Model Hypertension, February 1, 2001; 37(2): 270 - 274. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Haug, A. Schmid-Kotsas, U. Zorn, M. G. Bachem, S. Schuett, A. Gruenert, and E. Rozdzinski Hepatocyte growth factor is upregulated by low-density lipoproteins and inhibits endothelin-1 release Am J Physiol Heart Circ Physiol, December 1, 2000; 279(6): H2865 - H2871. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Yasuda, Y. Goto, T. Baba, T. Satoh, H. Sumida, S. Miyazaki, and H. Nonogi Enhanced secretion of cardiac hepatocyte growth factor from an infarct region is associated with less severe ventricular enlargement and improved cardiac function J. Am. Coll. Cardiol., July 1, 2000; 36(1): 115 - 121. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y Zhu, Y Hojo, U Ikeda, K Shimada;, and G F BAXTER Production of hepatocyte growth factor during acute myocardial infarction Heart, April 1, 2000; 83(4): 450 - 455. [Abstract] [Full Text]
|
|
|
|
 |
|
 T. Ohnishi, M. Suwa, T. Oyama, N. Arakaki, M. Torii, and Y. Daikuhara Prostaglandin E2 Predominantly Induces Production of Hepatocyte Growth Factor/Scatter Factor in Human Dental Pulp in Acute Inflammation Journal of Dental Research, February 1, 2000; 79(2): 748 - 755. [Abstract] [PDF]
|
|
|
|
 |
|
 S.-i. Hayashi, R. Morishita, S. Nakamura, K. Yamamoto, A. Moriguchi, T. Nagano, M. Taiji, H. Noguchi, K. Matsumoto, T. Nakamura, et al. Potential Role of Hepatocyte Growth Factor, a Novel Angiogenic Growth Factor, in Peripheral Arterial Disease : Downregulation of HGF in Response to Hypoxia in Vascular Cells Circulation, November 9, 1999; 100 (2009): II-301 - II-308. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Busse and I. Fleming A critical look at cardiovascular translational research Am J Physiol Heart Circ Physiol, November 1, 1999; 277(5): H1655 - H1660. [Full Text] [PDF]
|
|
|
|
|
|
K. Matsumoto, R. Morishita, A. Moriguchi, N. Tomita, Y. Yo, T. Nishii, K. Matsumoto, T. Nakamura, J. Higaki, and T. Ogihara Prevention of Renal Damage by Angiotensin II Blockade, Accompanied by Increased Renal Hepatocyte Growth Factor in Experimental Hypertensive Rats Hypertension, August 1, 1999; 34(2): 279 - 284. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Yoshitomi, S. Kojima, T. Umemoto, K. Kubo, Y. Matsumoto, M. Yano, T. Sugi, and M. Kuramochi Serum Hepatocyte Growth Factor in Patients with Peripheral Arterial Occlusive Disease J. Clin. Endocrinol. Metab., July 1, 1999; 84(7): 2425 - 2428. [Abstract] [Full Text]
|
|
|
|
|
|
M. Nishimura, M. Ushiyama, K. Ohtsuka, M. Nishida, N. Inoue, A. Matsumuro, T. Mineo, and M. Yoshimura Serum Hepatocyte Growth Factor as a Possible Indicator of Vascular Lesions J. Clin. Endocrinol. Metab., July 1, 1999; 84(7): 2475 - 2480. [Abstract] [Full Text]
|
|
|
|
 |
|
 K. Shinoda, S. Ishida, S. Kawashima, T. Wakabayashi, T. Matsuzaki, M. Takayama, K. Shinmura, and M. Yamada Comparison of the levels of hepatocyte growth factor and vascular endothelial growth factor in aqueous fluid and serum with grades of retinopathy in patients with diabetes mellitus Br J Ophthalmol, July 1, 1999; 83(7): 834 - 837. [Abstract] [Full Text]
|
|
|
|
|
|
S. Yasuda, Y. Goto, H. Sumida, T. Noguchi, T. Baba, S. Miyazaki, and H. Nonogi Angiotensin-Converting Enzyme Inhibition Restores Hepatocyte Growth Factor Production in Patients With Congestive Heart Failure Hypertension, June 1, 1999; 33(6): 1374 - 1378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Morishita, S. Nakamura, S.-i. Hayashi, Y. Taniyama, A. Moriguchi, T. Nagano, M. Taiji, H. Noguchi, S. Takeshita, K. Matsumoto, et al. Therapeutic Angiogenesis Induced by Human Recombinant Hepatocyte Growth Factor in Rabbit Hind Limb Ischemia Model as Cytokine Supplement Therapy Hypertension, June 1, 1999; 33(6): 1379 - 1384. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Morishita, S. Yamada, K. Yamamoto, N. Tomita, I. Kida, I. Sakurabayashi, A. Kikuchi, Y. Kaneda, R. Lawn, J. Higaki, et al. Novel Therapeutic Strategy for Atherosclerosis : Ribozyme Oligonucleotides Against Apolipoprotein(a) Selectively Inhibit Apolipoprotein(a) But Not Plasminogen Gene Expression Circulation, November 3, 1998; 98(18): 1898 - 1904. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Nakano, R. Morishita, A. Moriguchi, Y. Nakamura, S.-i. Hayashi, M. Aoki, I. Kida, K. Matsumoto, T. Nakamura, J. Higaki, et al. Negative Regulation of Local Hepatocyte Growth Factor Expression by Angiotensin II and Transforming Growth Factor-ß in Blood Vessels : Potential Role of HGF in Cardiovascular Disease Hypertension, September 1, 1998; 32(3): 444 - 451. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. VERGHESE, K. MCCORMICK-SHANNON, R. J. MASON, and M. A. MATTHAY Hepatocyte Growth Factor and Keratinocyte Growth Factor in the Pulmonary Edema Fluid of Patients with Acute Lung Injury . Biologic and Clinical Significance Am. J. Respir. Crit. Care Med., August 1, 1998; 158(2): 386 - 394. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Cavallaro, Z. Wu, A. D. Palo, R. Montesano, M. S. Pepper, J. A. M. maier, and M. R. Soria FGF-2 stimulates migration of Kaposi's sarcoma-like vascular cells by HGF-dependent relocalization of the urokinase receptor FASEB J, August 1, 1998; 12(11): 1027 - 1034. [Abstract] [Full Text]
|
|
|
|
|
|
N. Nakano, A. Moriguchi, R. Morishita, I. Kida, N. Tomita, K. Matsumoto, T. Nakamura, J. Higaki, and T. Ogihara Role of Angiotensin II in the Regulation of a Novel Vascular Modulator, Hepatocyte Growth Factor (HGF), in Experimental Hypertensive Rats Hypertension, December 1, 1997; 30(6): 1448 - 1454. [Abstract] [Full Text]
|
|